Immunovant Reports Strong IMVT-1402 RA Trial Results, Discontinues Batoclimab, and Provides Q4/FY26 Financials

summarizeSummary

Immunovant reported strong preliminary clinical trial results for its lead asset, IMVT-1402, in rheumatoid arthritis, while discontinuing its batoclimab program and detailing Q4 and full-year 2026 financial results.

check_boxKey Events

• Strong IMVT-1402 RA Trial Results

  Preliminary Week 16 results for IMVT-1402 in difficult-to-treat rheumatoid arthritis (D2T RA) showed high response rates: 72.7% ACR20, 54.5% ACR50, and 35.8% ACR70. Further updates are expected in the second half of calendar year 2026.

• Batoclimab Program Discontinued

  Following failed Phase 3 trials for thyroid eye disease, Immunovant has discontinued all development of batoclimab, incurring $39.0 million in contractual costs, to focus entirely on IMVT-1402.

• Solid Cash Position and Runway

  The company reported $902.1 million in cash and cash equivalents as of March 31, 2026, providing financial runway through the potential commercial launch of IMVT-1402 in Graves' Disease.

• Q4 and Full-Year 2026 Financials

  Immunovant reported a Q4 2026 net loss of $147.9 million ($0.73 per share) and a full-year 2026 net loss of $505.6 million ($2.77 per share), with increased R&D expenses driven by IMVT-1402 development and batoclimab discontinuation costs.

auto_awesomeAnalysis

Immunovant announced highly positive preliminary Week 16 results for its IMVT-1402 trial in difficult-to-treat rheumatoid arthritis (D2T RA), showing strong response rates (72.7% ACR20, 54.5% ACR50, 35.8% ACR70). This success for their lead asset is a major positive for the company's pipeline. Concurrently, Immunovant discontinued development of batoclimab across all indications after its Phase 3 thyroid eye disease trials failed to meet primary endpoints, incurring $39.0 million in contractual costs. This strategic pivot allows the company to fully focus resources on IMVT-1402. The company also reported a cash position of $902.1 million, providing runway through the potential commercial launch of IMVT-1402 in Graves' Disease. The stock is currently trading above its previous 52-week high, reflecting strong market confidence in the IMVT-1402 program.